SELLAS and Merck Plan Phase 1/2 Trial of Galinpepimut-S and Keytruda in Five Cancers

SELLAS and Merck Plan Phase 1/2 Trial of Galinpepimut-S and Keytruda in Five Cancers | Boulder Peptide Symposium

September 15-18, 2025

LIVE, In Person at the St. Julien Hotel in Boulder, Colorado

The only conference focused solely on the pharmaceutical development of peptide therapeutics.

SELLAS and Merck Plan Phase 1/2 Trial of Galinpepimut-S and Keytruda in Five Cancers

Galinpepimut-S is a peptide immunotherapy that SELLAS licensed from Memorial Sloan Kettering Cancer Center. It targets the Wilms tumor-1 (WT1) ...